Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jul 05, 2014 12:09pm
184 Views
Post# 22718335

RE:toinv SURVEY

RE:toinv SURVEYHi GV and other posters.

Yes GV I had a great birthday which was Canada Day, thanks. You have a great memory. I drank the champagne still believing we would not have any RVX announcements until fall. I hadn't checked the RVX trading nor Stockhouse until today and what a wonderful surprise!!! It's a belated birthday gift.

221 reads of the lament. Hope they feel as positive about rvx-208 as me. So I'm not sure why we only got 24 posters to complete the brief survey. Anyway I closed it out a few weeks ago when there were not new completes.

There have been many excellent and helpful posts this past week.

Some thoughts based on reviewing the recent postings.
  1. In my opinion KD would not be in this game unless he thought that he could make hundreds of millions if not billions of $. It's either going to be a huge victory OR nothing.
  2. In Don's February webcast when he defined the new target patients for RE-MACE he referred to a $14,000,000,000 potential annually in the USA alone. This was the same presentation where he talked about RVX having shifted to a focus on HDL-C to HDL-P 5 years ahead of other scientists and pharma that are now making the shift.
  3. The funding deal announced on July 3 is a clear and strong indication that Eastern, RVX and NGN are very, very strong believers in the future of rvx-208 for MACE reduction, plaque regression and many other diseases including diabetes, Alzheimers and various inflamatory chronic conditions.
  4. Recently, within the past 6 weeks, someone posted a link to a scientific paper related to BET inhibitors in a prestigious scientific journal. It was impossible for a layman to understand but what I did take away from it was a paragraph in the abstract that talked about all of the many diseases and conditions that BET inhibitors can improve. My take on this is that the underlying science behind rvx-208 continues to be confirmed and it's potential is huge and far beyond MACE.
  5. The structure of the deal suggests that Don and KD were not going to give up RVX cheap to BP and it also says they need to have a successful phase 2C to interest BP.

Congratulations to Don, his team, KD and NGN for keeping this moving.

We're finally starting to get some communications and more to come shorlty. IMO, many good things to come. DYODD. GLTA

Cheers
Toinv





Bullboard Posts